医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Pacific Prime’s Study Reveals Global Premium Hikes Impacting International Health Insurance Plans

2023年06月26日 AM11:00
このエントリーをはてなブックマークに追加


 

HONG KONG

Pacific Prime, an international health insurance brokerage, has released its Cost of Health Insurance Report 2023, highlighting a significant increase in premiums for individual and family plans worldwide. The report, based on data from 100 locations, indicates that 98% and 97% of surveyed locations experienced a premium increase in 2022 for individual and family plans, respectively.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230625171082/en/

Here is a visual overview of our key findings on the average costs of IPMI in 100 locations across the world in 2023. (Graphic: Business Wire)

Here is a visual overview of our key findings on the average costs of IPMI in 100 locations across the world in 2023. (Graphic: Business Wire)

The report begins by ranking locations according to their average international private medical insurance (IPMI) premiums in 2022. The US maintains the top position with an average premium of USD $9,817 for individuals and USD $28,250 for families. Meanwhile, Thailand continues to offer the most affordable individual IPMI premiums, with an average of USD $3,594. However, it moved up from the last spot in 2021 to the 50th in 2022 for family plans.

In addition to the overarching global trend in IPMI premiums, the report dives into region-specific trends, including:

  • The Americas are pushed out of the top 20 rankings
  • Hong Kong maintains the second spot for the third consecutive year
  • Singapore remains in the third spot for the second year in a row
  • Dubai earns the fourth spot in this year’s ranking
  • China moves out of its “correction phase”
  • UK premiums double 2021 growth rate
  • Thailand still has the cheapest individual IPMI premiums

By comparing data from 100 locations globally, the report aims to offer readers a comprehensive understanding of the worldwide cost of health insurance. The data generated for individuals and families in the report are based on standard IPMI rates – an inpatient and outpatient plan with no deductibles – for a 36-year-old male, who represents the primary target market for expat insurance products. This approach ensures ease of analysis and enables the presentation of the most accurate data possible.

Pacific Prime’s Cost of Health Insurance Report 2023 offers valuable insights into global and regional trends impacting IPMI premiums around the world. To explore these trends and their effects, download the Cost of International Health Insurance Report 2023 from Pacific Prime.

About Pacific Prime

Established in 2000, Pacific Prime is an award-winning global insurance brokerage and employee benefits specialist that offers individual and corporate insurance solutions. With USD $750 million premium under management, Pacific Prime is now the third largest employee benefits broker in the Asia Pacific after acquiring CXA Group’s brokerage arms in 2021. The brokerage has over 1,000 employees and 15 offices around the world including Hong Kong, Singapore, China, Thailand, Malaysia, UAE, the UK, the US, Mexico, and the Philippines.

To learn more about Pacific Prime, please visit: https://www.pacificprime.com/corporate

View source version on businesswire.com: https://www.businesswire.com/news/home/20230625171082/en/

CONTACT

Stephen Ho

Chief Marketing Officer

Pacific Prime

+852 3589 0508

同じカテゴリーの記事 

  • Celltrion presents 2-year post-hoc analysis findings for subcutaneous infliximab (CT-P13 SC), highlighting dose escalation as an option for managing loss of response in inflammatory bowel disease
  • Invisalign® Palatal Expander System by Align Technology Now Available in Singapore for Skeletal and Dental Expansion in Growing Patients
  • Invisalign® Palatal Expander System by Align Technology Now Available in Hong Kong for Skeletal and Dental Expansion in Growing Patients
  • MEDiC Life Sciences Announces Collaboration with Hanmi Pharmaceutical on Cancer Biomarker Discovery, Followed by Strategic Investment from Hanmi
  • CAI、ISPE年次総会・展示会にて新たなブランド・アイデンティティを発表